Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris

Journal of Biotechnology

Volumn 157, Issue 1, 2012, Pages 198-206

  Nett, Juergen H ^a   Gomathinayagam, Sujatha ^a   Hamilton, Stephen R ^a   Gong, Bing ^a   Davidson, Robert C ^a   Du, Min ^a   Hopkins, Daniel ^a   Mitchell, Teresa ^a   Mallem, Muralidhar R ^a   Nylen, Adam ^a   Shaikh, Seemab S ^a   Sharkey, Nathan ^a   Barnard, Gavin C ^a   Copeland, Victoria ^a   Liu, Liming ^a   Evers, Raymond ^a   Li, Yan ^a   Gray, Peter M ^a   Lingham, Russell B ^a   Visco, Denise ^a   Forrest, Gail ^a   DeMartino, Julie ^a   Linden, Thomas ^a   Potgieter, Thomas I ^a   Wildt, Stefan ^a   Stadheim, Terrance A ^a   d'Anjou, Marc ^a   Li, Huijuan ^a   Sethuraman, Natarajan ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Erythropoietin; Glycoengineered Pichia pastoris; Glycosylation

Indexed keywords

ERYTHROPOIETIN; HIGH HOMOGENEITY; MAMMALIAN HOSTS; ORDERS OF MAGNITUDE; P. PASTORIS; PEGYLATED PROTEINS; PICHIA PASTORIS; PROTEIN EXPRESSIONS; PURIFIED PROTEIN; RECOMBINANT HUMAN ERYTHROPOIETIN (RHEPO);

CELL PROLIFERATION; ESTERIFICATION; GLYCOLS; GLYCOSYLATION; MAMMALS; POLYETHYLENE GLYCOLS; PROTEINS; PURIFICATION;

YEAST;

MACROGOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW CELL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG PURIFICATION; ERYTHROPOIESIS; FEMALE; FERMENTATION OPTIMIZATION; FUNGUS CULTURE; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; RAT; REACTOR OPTIMIZATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; CELL PROLIFERATION; ERYTHROPOIETIN; FEMALE; GLYCOSYLATION; HUMANS; MALE; MICE; PICHIA; POLYETHYLENE GLYCOLS; POLYSACCHARIDES; PROTEIN ENGINEERING; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

ANIMALIA; MAMMALIA; PICHIA PASTORIS;

EID: 84855212712     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.11.002     Document Type: Article

References (50)

1. Bobrowicz P., Davidson R.C., Li H., Potgieter T.I., Nett J.H., Hamilton S.R., Stadheim T.A., Miele R.G., Bobrowicz B., Mitchell T., Rausch S., Renfer E., Wildt S. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology 2004, 14:757-766.
2. Celik E., Calik P., Halloran S.M., Oliver S.G. Production of recombinant human erythropoietin from Pichia pastoris and its structural analysis. J. Appl. Microbiol. 2007, 103:2084-2094.
3. Choi B.K., Bobrowicz P., Davidson R.C., Hamilton S.R., Kung D.H., Li H., Miele R.G., Nett J.H., Wildt S., Gerngross T.U. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Natl. Acad. Sci. U.S.A. 2003, 100:5022-5027.
4. Cregg J.M., Tolstorukov I., Kusari A., Sunga J., Madden K., Chappell T. Expression in the yeast Pichia pastoris. Methods Enzymol. 2009, 463:169-189.
5. Daly R., Hearn M.T. Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J. Mol. Recognit. 2005, 18:119-138.
6. Davidson R.C., Nett J.H., Renfer E., Li H., Stadheim T.A., Miller B.J., Miele R.G., Hamilton S.R., Choi B.K., Mitchell T.I., Wildt S. Functional analysis of the ALG3 gene encoding the Dol-P-Man: Man5GlcNAc2-PP-Dol mannosyltransferase enzyme of P. pastoris. Glycobiology 2004, 14:399-407.
7. Davis J.M., Arakawa T., Strickland T.W., Yphantis D.A. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987, 26:2633-2638.
8. Duvar S., Berlin J., Ziehr H., Conradt H.S. Modulation of the glycosylation repertoire of a recombinant human EPO expressing model cell line under different culture conditions. Animal Cell Technology Meets Genomics, ESACT Proceedings, vol. 2 2005, 723-725.
9. Egrie J.C., Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Brit. J. Cancer 2001, 84(Suppl. 1):3-10.
10. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 2003, 228:1-14.
11. Ghaderi D., Taylor R.E., Padler-Karavani V., Diaz S., Varki A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 2010, 28:863-867.
12. Goldwasser E. Erythropoietin and its mode of action. Blood Cells 1984, 10:147-162.
13. Hamilton S.R., Bobrowicz P., Bobrowicz B., Davidson R.C., Li H., Mitchell T., Nett J.H., Rausch S., Stadheim T.A., Wischnewski H., Wildt S., Gerngross T.U. Production of complex human glycoproteins in yeast. Science 2003, 301:1244-1246.
14. Hamilton S.R., Davidson R.C., Sethuraman N., Nett J.H., Jiang Y., Rios S., Bobrowicz P., Stadheim T.A., Li H., Choi B.K., Hopkins D., Wischnewski H., Roser J., Mitchell T., Strawbridge R.R., Hoopes J., Wildt S., Gerngross T.U. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 2006, 313:1441-1443.
15. Hopkins D., Gomathinayagam S., Rittenhour A.M., Du M., Hoyt E., Karaveg K., Mitchell T., Nett J.H., Sharkey N.J., Stadheim T.A., Li H., Hamilton S.R. Elimination of β-mannose glycan structures in Pichia pastoris. Glycobiology 2011, First published online: August 12, 2011. 10.1093/glycob/cwr108.
16. Han Y., Kanbe T., Cherniak R., Cutler J.E. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun. 1997, 65:4100-4107.
17. Hokke C.H., Bergwerff A.A., van Dedem G.W.K., van Oostrum J., Kamerling J.P., Vliegenthart J.F.G. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett. 1990, 275:9-14.
18. Hossler P., Khattak S.F., Li Z.J. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009, 19:936-949.
19. Kinstler O.B., Brems D.N., Lauren S.L.v. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 1996, 13:996-1002.
20. Koury M.J., Bondurant M.C. A survival model of erythropoietin action. Science 1990, 248:378-381.
21. Kozlowski A., Harris J.M. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 2001, 14:217-224.
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
23. Lawrence S. Biotech blockbusters consolidate markets. Nat. Biotechnol. 2006, 24:1466.
24. Li H., Miele R.G., Mitchell T.I., Gerngross T.U. N-linked glycan characterization of heterologous proteins. Methods Mol. Biol. 2007, 389:139-150.
25. Li H., Sethuraman N., Stadheim T.A., Zha D., Prinz B., Ballew N., Bobrowicz P., Choi B.K., Cook W.J., Cukan M., Houston-Cummings N.R., Davidson R., Gong B., Hamilton S.R., Hoopes J.P., Jiang Y., Kim N., Mansfield R., Nett J.H., Rios S., Strawbridge R., Wildt S., Gerngross T.U. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol. 2006, 24:210-215.
26. MacDougall I.C., Gray S.J., Elston O., Breen C., Jenkins B., Browne J., Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 1999, 10:2392-2395.
27. MacDougall I.C. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep. 2005, 4:436-440.
28. Maleki A., Najafabadi A.R., Roohvand F., Shafiee A., Khanahmad H., Faghihi H., Hedayati M.H., Tajerzadeh H. Evaluation of bioactivity and pharmacokinetic characteristics of PEGylated P. pastoris - expressed erythropoietin. Drug Deliv. 2011, (Epub ahead of print).
29. Mille C., Bobrowicz P., Trinel P.A., Li H., Maes E., Guerardel Y., Fradin C., Martínez-Esparza M., Davidson R.C., Janbon G., Puolain D., Wildt S. Identification of a new family of genes involved in beta-1,2-mannosylation of glycans in Pichia pastoris and Candida albicans. J. Biol. Chem. 2008, 283:9724-9736.
30. Nett J.H., Gerngross T.U. Cloning and disruption of the PpURA5 gene and construction of a set of integration vectors for the stable genetic modification of Pichia pastoris. Yeast 2003, 20:1279-1290.
31. Nett J.H., Stadheim T.A., Li H., Bobrowicz P., Hamilton S.R., Davidson R.C., Choi B.K., Mitchell T., Bobrowicz B., Rittenhour A., Wildt S., Gerngross T.U. A combinatorial genetic library approach to target heterologous glycosylation enzymes to the endoplasmic reticulum or the Golgi apparatus of Pichia pastoris. Yeast 2011, 28:237-252.
32. Noguchi A., Mukuria C.J., Suzuki E., Naiki M. Failure of human immunoresponse to N-glycolylneuraminic acid epitope contained in recombinant human erythropoietin. Nephron 1996, 72:599-603.
33. Padler-Karavani V., Yu H., Cao H., Chokhawala H., Karp F., Varki N., Chen X., Varki A. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008, 18:818-830.
34. Pasut G., Veronese F.M. PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today (Barc.) 2009, 45:687-695.
35. Potgieter T.I., Cukan M., Drummond J.E., Houston-Cummings N.R., Jiang Y., Li F., Lynaugh H., Mallem M., McKelvey T.W., Mitchell T., Nylen A., Rittenhour A., Stadheim T.A., Zha D., d'Anjou M. Production of monoclonal antibodies by glycoengineered Pichia pastoris. J. Biotechnol. 2009, 139(4):318-325.
36. Seong S.R., Lee J.W., Lee Y.K., Kim T.I., Son D.J., Moon D.C., Yun Y.W., Yoon D.Y., Hong J.T. Stimulation of cell growth by erythropoietin in RAW264.7 cells: association with AP-1 activation. Arch. Pharm. Res. 2006, 29:218-223.
37. Skibeli V., Nissen-Lie G., Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001, 98:3626-3634.
38. Sigounas G., Steiner M., Anagnostou A. Synergism of hemopoietic growth factors on endothelial cell proliferation. Angiology 1997, 48:141-147.
39. Solá R.J., Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 2010, 24:9-21.
40. Stadheim T.A., Li H., Kett W., Burnina I.N., Gerngross T.U. Use of high-performance anion exchange chromatography with pulsed amperometric detection for O-glycan determination in yeast. Nat. Protoc. 2008, 3(6):1026-1031.
41. Stephenson J.R., Axelrad A.A., McLeod D.L., Shreeve M.M. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc. Natl. Acad. Sci. U.S.A. 1971, 68:1542-1546.
42. Stübinger G., Marchetti M., Nagano M., Reichel C., Gmeiner G., Allmaier G. Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:728-742.
43. Takeuchi M., Takasaki S., Miyazaki H., Kato T., Hoshi S., Kochibe N., Kobata A. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J. Biol. Chem. 1988, 263:3657-3663.
44. Takeuchi M., Inoue N., Strickland T.W., Kubota M., Wada M., Shimizu R., Hoshi S., Kozutsumi H., Takasaki S., Kobata A. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7819-7822.
45. Tangvoranuntakul P., Gagneux P., Diaz S., Bardor M., Varki N., Varki A., Muchmore E. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12045-12050.
46. Varki A. Uniquely human evolution of sialic acid genetics and biology. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(Suppl. 2):8939-8946.
47. Wasley L.C., Timony G., Murtha P., Stoudemire J., Dorner A.J., Caro J., Krieger M., Kaufman R.J. The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 1991, 77:2624-2632.
48. Wileman T., Harding C., Stahl P. Receptor-mediated endocytosis. Biochem. J. 1985, 232(1):1-14.
49. Yoon S.K., Hong J.K., Lee G.M. Effect of simultaneous application of stressful culture conditions on specific productivity and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol. Prog. 2004, 20:1293-1296.
50. Yuen C.T., Storring P.L., Tiplady R.J., Izquierdo M., Wait R., Gee C.K., Gerson P., Lloyd P., Cremata J.A. Relationships between the N-glycan structures and biological activities of recombinant human erythropoietins produced using different culture conditions and purification procedures. Brit. J. Haematol. 2003, 121:511-526.